META HEALTH LIMITED

(Incorporated in the Republic of Singapore on 22/12/1988)
(Company Registration Number: 198804700N)

Condensed Interim Consolidated Financial Statements for the Third Quarter ("3Q") and Nine-Month ("9M") Financial Period Ended 30 September 2026 (Unaudited)

*Meta Health Limited (the "**Company**") is required to announce its financial statements on a quarterly basis pursuant to Rule 705(2)(e) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist ("**Catalist Rules**"), as the independent auditor's report on the latest audited consolidated financial statements of the Company and its subsidiaries for the financial year ended 31 December 2025 included a material uncertainty related to going concern.*

*This announcement has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lim Hui Zheng, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.

TABLE OF CONTENTS

A. Condensed interim statements of financial position

B. Condensed interim consolidated statement of comprehensive income

C. Condensed interim statements of changes in equity

D. Condensed interim consolidated statement of cash flows

E. Notes to the condensed interim consolidated financial statements

F. Other information required pursuant to Appendix 7C of the Catalist Rules

A. Condensed interim statements of financial position

	Note	The Group		The Company	
		30-Sep-26 S$'000 (Unaudited)	31-Dec-25 S$'000 (Audited)	30-Sep-26 S$'000 (Unaudited)	31-Dec-25 S$'000 (Audited)
ASSETS					
Non-Current Assets					
Property, plant and equipment	**5**	3	4	- *	- *
Right-of-use assets		76	122	-	-
Subsidiaries	**6**	-	-	66	66
Intangible assets	**7**	206	208	-	-
Other investments	**8**	-	-	-	-
		285	334	66	66
Current Assets					
Trade and other receivables	**9**	1,188	1,226	40	40
Prepayments		13	13	12	13
Derivative financial assets	**10**	17	17	17	17
Cash and bank balances	**11**	162	194	32	51
		1,380	1,450	101	121
Total assets		**1,665**	**1,784**	**167**	**187**
EQUITY AND LIABILITIES					
Capital and Reserves					
Share capital	**12**	33,297	33,297	33,297	33,297
Reserves		(35,224)	(34,646)	(36,391)	(35,576)
Total equity attributable to owners of the Company		(1,927)	(1,349)	(3,094)	(2,279)
Non-controlling interests		(109)	(123)	-	-
		(2,036)	**(1,472)**	**(3,094)**	**(2,279)**
Non-Current Liabilities					
Borrowings	**13**	19	112	-	-
Lease liabilities		17	65	-	-
		36	177	-	-
Current Liabilities					
Borrowings	**13**	2,306	1,946	2,170	1,750
Lease liabilities		64	61	-	-
Trade and other payables	**14**	1,295	1,072	1,091	716
		3,665	3,079	3,261	2,466
Total liabilities		**3,701**	**3,256**	**3,261**	**2,466**
Total equity and liabilities		**1,665**	**1,784**	**167**	**187**

* *Amount is less than S$1,000.*

B. Condensed interim consolidated statement of comprehensive income

	Note	The Group 3Q2026 S$'000 (Unaudited)	3Q2025 S$'000 (Unaudited)	Change %	The Group 9M2026 S$'000 (Unaudited)	9M2025 S$'000 (Unaudited)	Change %
Continuing operations							
Revenue	**4, 15**	369	346	7%	1,089	1,020	7%
Other income	**16**	207	25	728%	297	40	643%
Raw materials and consumables used		(28)	(28)	-	(84)	(69)	22%
Employee benefits expense		(281)	(477)	-41%	(865)	(1,184)	-27%
Depreciation of property, plant and equipment		-*	-*	n.m.	(1)	(2)	-50%
Amortisation of intangible assets		-*	-*	n.m.	(2)	-	n.m.
Depreciation of right-of-use assets		(16)	(15)	7%	(46)	(46)	0%
Other charges		-*	(2)	n.m.	-*	(3)	n.m.
Finance costs		(60)	(35)	71%	(163)	(83)	96%
Other operating expenses		(302)	(231)	31%	(788)	(689)	14%
Loss before taxation		(111)	(417)	-73%	(563)	(1,016)	-45%
Tax expense	**17**	-	-	-	-	-	-
Loss for the period	**18**	(111)	(417)	-73%	(563)	(1,016)	-45%
Other comprehensive (loss)/income:							
Items that may be reclassified subsequently to profit or loss							
Currency translation differences - Foreign operations		(4)	5	-180%	(1)	(1)	n.m.
Other comprehensive (loss)/income for the period, net of tax		(4)	5	-180%	(1)	(1)	n.m.
Total comprehensive loss for the period		(115)	(412)	-72%	(564)	(1,017)	-45%
(Loss) / profit attributable to:							
Owners of the Company		(113)	(418)	-73%	(577)	(1,012)	-43%
Non-controlling interests		2	1	52%	14	(4)	n.m.
		(111)	(417)	-73%	(563)	(1,016)	-45%
Total comprehensive (loss)/income attributable to:							
Owners of the Company		(117)	(413)	-72%	(578)	(1,013)	-43%
Non-controlling interests		2	1	52%	14	(4)	n.m.
		(115)	(412)	-72%	(564)	(1,017)	-45%
Loss per share attributable to owners of the Company (Singapore cent)							
- Basic and diluted		(0.01)	(0.02)		(0.04)	(0.08)	

* *Amount is less than S$1,000.*
n.m. denotes not meaningful.

Notes:

(1) "3Q2026" refers to the three-month financial period ended 30 September 2026.
(2) "3Q2025" refers to the three-month financial period ended 30 September 2025.
(3) "9M2026" refers to the nine-month financial period ended 30 September 2026.
(4) "9M2025" refers to the nine-month financial period ended 30 September 2025.
(5) The basic and diluted loss per share was calculated based on weighted average number of shares in issue of 1,320,390,145 in 3Q2026 and 9M2026, and 1,301,830,444 in 3Q2025 and 9M2025.

C. Condensed interim statements of changes in equity

The Group	Share capital S$'000	Fair value reserve S$'000	Foreign currency translation reserve S$'000	Statutory reserve S$'000	Other reserve S$'000	Accumulated losses S$'000	Total equity attributable to owners of the Company S$'000	Non-controlling interest S$'000	Total equity S$'000
Balance at 1 January 2026 (Audited)	**33,297**	**(2,475)**	**(348)**	**566**	**(885)**	**(31,504)**	**(1,349)**	**(123)**	**(1,472)**
(Loss) /Profit for the period	-	-	-	-	-	(577)	(577)	14	(563)
Other comprehensive income for the period									
- Currency translation differences	-	-	(1)	-	-	-	(1)	-	(1)
Total comprehensive loss for the period	**-**	**-**	**(1)**	**-**	**-**	**(577)**	**(578)**	**14**	**(564)**
Balance at 30 September 2026 (Unaudited)	**33,297**	**(2,475)**	**(349)**	**566**	**(885)**	**(32,081)**	**(1,927)**	**(109)**	**(2,036)**
Balance at 1 January 2025 (Audited)	**31,841**	**(2,475)**	**(360)**	**566**	**(885)**	**(30,255)**	**(1,568)**	**(119)**	**(1,687)**
Loss for the year	-	-	-	-	-	(1,249)	(1,249)	(4)	(1,253)
Other comprehensive income for the year									
- Currency translation differences	-	-	12	-	-	-	12	-	12
Total comprehensive loss for the year	**-**	**-**	**12**	**-**	**-**	**(1,249)**	**(1,237)**	**(4)**	**(1,241)**
Contributions by and distributions to owners									
- Issuance of shares	1,456	-	-	-	-	-	1,456	-	1,456
Transactions with owners in their capacity as owners	**1,456**	**-**	**-**	**-**	**-**	**-**	**1,456**	**-**	**1,456**
Balance at 31 December 2025 (Audited)	**33,297**	**(2,475)**	**(348)**	**566**	**(885)**	**(31,504)**	**(1,349)**	**(123)**	**(1,472)**

C. Condensed interim statements of changes in equity (cont.)

The Company	Share capital	Accumulated losses	Total equity
	S$'000	S$'000	S$'000
Balance at 1 January 2026 (Audited)	**33,297**	**(35,576)**	**(2,279)**
Loss for the period	-	(815)	(815)
Total comprehensive loss for the period	**-**	**(815)**	**(815)**
Balance at 30 September 2026	**33,297**	**(36,391)**	**(3,094)**
Balance at 1 January 2025 (Audited)	**31,841**	**(34,125)**	**(2,284)**
Loss for the period	-	(1,451)	(1,451)
Total comprehensive loss for the period	**-**	**(1,451)**	**(1,451)**
Contributions by and distributions to owners			
- Issuance of shares	1,456	-	1,456
Transactions with owners in their capacity as owners	**1,456**	**-**	**1,456**
Balance at 31 December 2025 (Audited)	**33,297**	**(35,576)**	**(2,279)**

D. Condensed interim consolidated statement of cash flows

	The Group		The Group	
	3Q2026 S$'000 (Unaudited)	3Q2025 S$'000 (Unaudited)	9M2026 S$'000 (Unaudited)	9M2025 S$'000 (Unaudited)
Cash Flows from Operating Activities				
Loss before taxation from continuing operations	(111)	(417)	(563)	(1,016)
Adjustments for:				
Depreciation of property, plant and equipment	-*	-*	1	2
Amortisation of intangible assets	-*	-	2	-
Depreciation of right-of-use assets	16	15	46	46
Impairment of other receivables	-	-	14	-
Interest expense on borrowings	59	32	159	75
Interest expense on lease liabilities	1	3	4	8
Interest income	-*	-*	-*	-*
Operating loss before working capital changes	(35)	(367)	(337)	(885)
Changes in trade and other receivables	15	(58)	24	(160)
Changes in prepayments	(7)	4	-	(25)
Changes in trade and other payables	(1)	245	223	(38)
Net cash used in operations	(28)	(176)	(90)	(1,108)
Income taxes paid	-	-	-	-
Net cash used in operating activities	**(28)**	**(176)**	**(90)**	**(1,108)**
Cash Flows from Investing Activities				
Interest received	-*	-*	-*	-*
Purchase of property, plant and equipment	-	(2)	-	(2)
Net cash used in investing activities	**-**	**(2)**	**-**	**(2)**
Cash Flows from Financing Activities				
Interest paid	(60)	(35)	(163)	(83)
Net proceeds from issuance of shares	-	-	-	1,458
Proceeds from borrowings	70	350	420	800
Repayment of borrowings	(48)	(145)	(153)	(1,049)
Repayment of lease liabilities	(15)	(23)	(45)	(66)
Net cash (used in) / provided by financing activities	**(53)**	**147**	**59**	**1,060**
Net decrease in cash and cash equivalents	(81)	(31)	(31)	(50)
Cash and cash equivalents at beginning of period	247	165	194	187
Exchange differences on translation of cash and cash equivalents	(4)	-	(1)	(1)
Cash and cash equivalents at end of period (Note 11)	**162**	**134**	**162**	**136**

Note:
** Amount is less than S$1,000.*

E. Notes to the Condensed Interim Consolidated Financial Statements

1. Corporate information

Meta Health Limited (the "**Company**") is incorporated in Singapore.

These unaudited condensed interim consolidated financial statements as at and for the third quarter ("**3Q**") and nine-month ("**9M**") financial period ended 30 September 2026 comprise the Company and its subsidiaries (the "**Group**").

The principal activity of the Company is those relating to investment holding.

The principal activity of the key operating subsidiary is the provision of health screening services as part of the Group's healthcare operations.

2. Basis of preparation

The unaudited condensed interim consolidated financial statements for 3Q2026 and 9M2026 have been prepared in accordance with the Singapore Financial Reporting Standards International ("**SFRS(I)**") 1-34 Interim Financial Reporting. The unaudited condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant for understanding the changes in the Group's financial position and performance since the last audited consolidated financial statements of the Group for the financial year ended 31 December 2025 ("**FY2025**").

The accounting policies and methods of computation adopted are consistent with those applied in the Group's most recently audited consolidated financial statements of the Group for FY2025, which were prepared in accordance with SFRS(I)s.

The unaudited condensed interim consolidated financial statements are presented in Singapore dollars, which is the Company's functional currency.

Going concern assumption

As at 30 September 2026, the Group reported net liabilities of S$2.0 million (31 December 2025: S$1.5 million) and net current liabilities of S$2.3 million (31 December 2025: S$1.6 million). In 9M2026, the Group also reported a net loss of S$0.6 million (9M2025: S$1.0 million) and net cash used in operating activities of S$90,000 (9M2025: S$1.1 million).

As at 30 September 2026, the Company reported net liabilities of S$3.1 million (31 December 2025: S$2.3 million) and net current liabilities of S$3.2 million (31 December 2025: S$2.3 million).

The Group had S$0.2 million (31 December 2025: S$0.6 million) of undrawn credit facilities as at 30 September 2026.

The aforementioned conditions indicate the existence of a material uncertainty that may cast significant doubt on the ability of the Group to continue as a going concern and the Group may not realise its assets and settle its liabilities in the ordinary course of business at the amounts recorded in the financial statements.

Nevertheless, the directors and the management of the Company are of the view that the use of the going concern assumption in the preparation of the unaudited condensed interim consolidated financial statements for 3Q2026 of the Group and the Company is appropriate, based on a detailed evaluation of available liquidity and financing sources, as well as reasonable estimates of forthcoming transactions and mitigating measures, barring unforeseen circumstances. In assessing the appropriateness of the going concern assumption applied in the preparation of the condensed interim consolidated financial statements of the Group and the Company, the key considerations include:

(i) The Group continues to implement cost management initiatives and operational improvements to enhance its financial performance and cash flows;

(ii) A controlling shareholder of the Company has undertaken to provide continuing financial support to the Group and the Company, as and when required, to enable them to continue their operations and meet their liabilities and obligations as they fall due, for at least twelve (12) months from the date of the approval of the Group's financial statements, being 9 April 2026;

(iii) As at 30 September 2026, the Group has drawn down S$420,000 out of the S$650,000 loan facility granted by the controlling shareholder of the Company, with the remaining S$230,000 available for drawdown; and

(iv) The Group's existing borrowing of S$850,000, which was contractually due to mature in February and March 2026, was refinanced with repayment terms extending beyond twelve (12) months from 31 March 2026, and the Company intends to engage the lender to negotiate extension/refinancing arrangements, at least three (3) months before the loan becomes due and payable.

Subsequent to 30 September 2026, the Company announced on 26 October 2026 the proposed placement of 640,000,000 new ordinary shares in the capital of the Company at an issue price of S$0.0036 per share, to raise aggregate gross proceeds of approximately S$2.30 million (the "**Proposed Placement**"). The Proposed Placement, if completed, is expected to strengthen the Group's financial position through the repayment of certain shareholder loans and accrued interest and the provision of additional working capital. As at the date of this announcement, the Proposed Placement has not been completed and remains subject to the fulfilment of the conditions precedent under the respective subscription agreements.

Accordingly, the directors and the management of the Company consider it appropriate that the unaudited condensed interim consolidated financial statements of the Group and the Company for 3Q2026 and 9M2026 should be prepared on a going concern basis and do not include any adjustments to the carrying amounts and classification of assets, liabilities and reported expenses that may otherwise be required if the going concern basis were not appropriate.

2.1. New and amended standards adopted by the Group

The Group has adopted new and revised SFRS(I) and interpretations of SFRS(I) applicable to the Group and the Company, which are effective for the financial year beginning 1 January 2026. The adoption of these new SFRS(I) standards, amendments, and interpretations is not expected to have a material impact on the Group's unaudited condensed interim consolidated financial statements for current financial period and prior financial year.

2.2. Use of judgements and estimates

In preparing the unaudited condensed interim consolidated financial statements, management has made judgements, estimates, and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty are the same as those that applied to the most recently audited annual consolidated financial statements of the Group as at and for the financial year ended 31 December 2025, except for the impairment of non-financial assets and the fair value of unquoted investments.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the financial period in which the estimates are revised and in any future financial periods affected.

Information about estimates, assumptions, and judgements in applying accounting policies that have the most significant effect on the amounts recognised in the financial statements are as follows:

- Depreciation of property, plant and equipment and right-of-use assets;
- Impairment assessment of property, plant and equipment and right-of-use assets;
- Impairment assessment of subsidiaries;
- Impairment assessment of intangible assets;
- Impairment assessment of trade and other receivables; and
- Purchase price allocation for business combination.

3. Seasonal operations

The Group's businesses are not significantly affected by seasonal or cyclical factors during the financial period reported on.

4. Segment and revenue information

For management reporting purposes, the Group is organised into Healthcare and Others for 3Q2026 and 9M2026, and 3Q2025 and 9M2025. During 3Q2026 and 9M2026, the Group's only operating business unit, Healthcare, operates in Singapore and all its non-current assets are located in Singapore.

There are no operating segments that have been aggregated to form the above reportable operating segments.

The Company's Board of Directors monitors the operating results of the Group's business units for the purpose of making decisions about resource allocation and performance assessment.

Information regarding the results of each reportable segment is included in the following tables. Performance is measured based on segment profit (before interest, taxation and unallocated expenses), as included in the internal management reports that are reviewed by the Company's Board of Directors, which in certain respects, as explained in the following tables, is different from profit in the consolidated financial statements. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities operating within these industries.

Inter-segment pricing is determined on an arm's length basis.

The Group's finance costs and income taxes are managed on a group basis and are not allocated to operating segments.

4.1 Reportable segments

	3Q2026 (Unaudited)			3Q2025 (Unaudited)		
	Healthcare (Continuing)	**Others (Continuing)**	**The Group**	**Healthcare (Continuing)**	**Others (Continuing)**	**The Group**
	S$'000	**S$'000**	**S$'000**	**S$'000**	**S$'000**	**S$'000**
Total revenue	369	-	369	346	-	346
Segment profit/(loss)	202 [(b)]	(67)	135	27[(b)]	(56)	(29)
Finance cost	(3)	(57)	(60)	(7)	(28)	(35)
Unallocated expenses [(a)]	(8)	(178)	(186)	(4)	(349)	(353)
Loss before tax	191	(302)	(111)	16	(433)	(417)
Taxation	-	-	-	-	-	-
Loss for the period	191	(302)	(111)	16	(433)	(417)
Amortisation of intangible assets	-*	-	-	-	-	-
Depreciation of property, plant and equipment	-*	-*	-	-*	-*	-
Depreciation of right-of-use assets	16	-	16	15	-	15
At 30 September 2026 / 31 December 2025						
Other segment information:						
Segment assets	936	729	1,665	1,017	767	1,784
Segment liabilities	544	3,157	3,701	898	2,358	3,256
Non-current assets:						
Property, plant and equipment	3	- *	3	4	- *	4
Right-of-use assets	76	-	76	122	-	122

* Amount is less than S$1,000.

Notes:

(a) Unallocated expenses primarily relate to directors' fees, directors' remuneration, listing expenses and other corporate related expenses.

(b) Segment profit of the Healthcare business unit in 3Q2026 includes a one-off income of approximately S$207,000 (3Q2025: S$25,000) arising from the recovery of losses related to irregularities concerning a subsidiary of the Group, Gainhealth Pte. Ltd. The one-off income comprised approximately S$7,000 received as the final settlement payment during 3Q2026 and approximately S$200,000 of non-cash income arising from the reversal of a pre-existing payable following the full receipt by the Group of all settlement sums due under the settlement agreement dated 8 September 2025. Please refer to Note 31 of the audited financial statements in the Group's Annual Report for FY2025 for further details on the irregularities concerning Gainhealth Pte. Ltd. and the settlement agreement.

4.1 Reportable segments (contd)

	9M2026 (Unaudited)			9M2025 (Unaudited)		
	Healthcare S$'000	**Others S$'000**	**The Group S$'000**	**Healthcare S$'000**	**Others S$'000**	**The Group S$'000**
Total revenue	1,089	-	1,089	1,020	-	1,020
Segment profit/(loss)	318 [(b)]	(210)	108	1 [(b)]	(176)	(175)
Finance cost	(13)	(150)	(163)	(23)	(60)	(83)
Unallocated expenses [(a)]	(22)	(486)	(508)	(14)	(744)	(758)
Profit/(loss) before tax	283	(846)	(563)	(36)	(980)	(1,016)
Taxation	-	-	-	-	-	-
Profit/(loss) for the period	283	(846)	(563)	(36)	(980)	(1,016)
Amortisation of intangible assets	2	-	2	-	-	-
Depreciation of property, plant and equipment	1	-*	1	2	-*	2
Depreciation of right-of-use assets	46	-	46	46	-	46
Impairment of other receivables	14	-	14	-	-	-
At 30 September 2026 / 31 December 2025						
Other segment information:						
Segment assets	936	729	1,665	1,017	767	1,784
Segment liabilities	544	3,157	3,701	898	2,358	3,256
Non-current assets:						
Property, plant and equipment	3	- *	3	4	- *	4
Right-of-use assets	76	-	76	122	-	122

* Amount is less than S$1,000.

Notes:

(a) Unallocated expenses primarily relate to directors' fees, directors' remuneration, listing expenses and other corporate related expenses.

(b) Segment profit of the Healthcare business unit in 9M2026 includes a one-off income of approximately S$292,000 (9M2025: S$25,000) arising from the recovery of losses related to irregularities concerning a subsidiary of the Group, Gainhealth Pte. Ltd. The one-off income comprised approximately S$92,000 received as the final settlement payment during 9M2026 and approximately S$200,000 of non-cash income arising from the reversal of a pre-existing payable following the full receipt by the Group of all settlement sums due under the settlement agreement dated 8 September 2025. Please refer to Note 31 of the audited financial statements in the Group's Annual Report for FY2025 for further details on the irregularities concerning Gainhealth Pte. Ltd. and the settlement agreement.

5. Property, plant and equipment

During 9M2026, the Group did not acquire or dispose of any property, plant and equipment. During 9M2025, the Group acquired approximately S$2,000 of property, plant and equipment. There were no disposal of any property, plant and equipment during 9M2025.

6. Subsidiaries

	The Company	
	30-Sep-26	**31-Dec-25**
	S$'000	**S$'000**
Unquoted equity investments, at cost		
At 1 January 2025 / 31 December 2025 / 30 September 2026	22,776	22,776
Allowance for impairment losses		
At 1 January 2025 / 31 December 2025 / 30 September 2026	22,710	22,710
Carrying amount as of 31 December 2025 / 30 September 2026	**66**	**66**

7. Intangible assets

The Group	**Goodwill** **S$'000**	**Non-contractual customer relationships** **S$'000**	**Total** **S$'000**
Cost			
At 1 January 2025	7,746	8	7,754
Derecognition	(98)	-	(98)
At 31 December 2025 and 30 September 2026	**7,648**	**8**	**7,656**
Accumulated amortisation and impairment loss			
At 1 January 2025	7,543	-	7,543
Derecognition	(98)	-	(98)
Amortisation	-	3	3
At 31 December 2025	**7,445**	**3**	**7,448**
Amortisation	-	2	2
At 30 September 2026	**7,445**	**5**	**7,450**
Carrying amount			
At 30 September 2026	**203**	**3**	**206**
At 31 December 2025	**203**	**5**	**208**

During FY2025, the Company struck off a subsidiary, TS Medical (City Gate) Pte. Ltd. ("**TS Medical**"). Accordingly, goodwill previously recognised on the acquisition of the said subsidiary, amounting to $98,000, and the associated accumulated impairment losses of $98,000 were derecognised upon the strike-off, with no impact on profit or loss.

8. Other investments

	The Group	
	30-Sep-26 S$'000	31-Dec-25 S$'000
Unquoted equity instruments at fair value through other comprehensive income		
At 1 January 2025 / 31 December 2025 / 30 September 2026	-	-

	The Group	
	30-Sep-26 S$'000	31-Dec-25 S$'000
Non-current		
Unquoted equity instruments		
- Adazal Private Limited - incorporated in Singapore (1)	-	-
- Medtel Healthcare Private Limited - Incorporated in India (2)	-	-
	-	-

Notes:
(1) The unquoted equity shares represent investment in a corporation which is engaged in online commerce activities, and comprises less than 18.41% ownership interests in the investee.
(2) The unquoted equity shares represent investment in a corporation which is engaged in medication activities, and comprises less than 8.04% ownership interests in the investee.

The above unquoted equity investments are not held for trading. Instead, they are held for medium- to long-term strategic purposes. Accordingly, the Group has designated them at fair value through other comprehensive income ("**FVOCI**"), because the Group views that recognising short-term fluctuations in their fair value in profit or loss is not consistent with the Group's strategy of holding these investments for medium to long-term strategic purposes and realising their performance potential in the long run.

9. Trade and other receivables

	The Group		The Company	
	30-Sep-26 S$'000	31-Dec-25 S$'000	30-Sep-26 S$'000	31-Dec-25 S$'000
Trade receivables				
- third parties	16	13	-	-
Amount due from subsidiaries (non-trade)	-	-	4,821	4,815
Less: allowance for expected credit losses	-	-	(4,807)	(4,815)
Deposits	403	419	5	21
Less: allowance for expected credit losses	(385)	(385)	(5)	(5)
Other receivables	41	43	26	24
Less: allowance for expected credit losses	(14)	-	-	-
GST recoverable	1,127	1,136	-	-
	1,172	1,213	40	40
	1,188	**1,226**	**40**	**40**

10. Derivative financial assets

	The Group and The Company	
	30-Sep-26	31-Dec-25
	S$'000	S$'000
Derivative:		
- Put and call options, at fair value	17	17
	17	**17**

The Company entered into a put and call option agreement with the vendor as part of the acquisition of Jas Medical Screening Centre Pte Ltd ("**Jas Medical**").

11. Cash and bank balances

	The Group		The Company	
	30-Sep-26	31-Dec-25	30-Sep-26	31-Dec-25
	S$'000	S$'000	S$'000	S$'000
Cash in banks	162	194	32	51
Cash on hand	- *	- *	-	-
	162	**194**	**32**	**51**

* Amount is less than S$1,000.

12. Share capital

	The Group and the Company			
	30-Sep-26		31-Dec-25	
	Number of Shares	Amount	Number of Shares	Amount
	'000	$'000	'000	$'000
Issued and fully paid, with no par value				
At 1 January	1,320,390	33,297	1,056,312	31,841
Issuance of shares	-	-	264,078	1,456
At 30 September / 31 December	**1,320,390**	**33,297**	**1,320,390**	**33,297**

Shares issued during FY2025:

On 13 February 2025, the Company issued 264,078,029 new ordinary shares at an issue price of $0.006 per share, through a rights issue exercise. Share issuance costs amounted to approximately S$129,000.

Save for the above, the Company does not have outstanding convertibles, treasury shares or subsidiary holdings as at 30 September 2025, 31 December 2025 and 30 September 2026.

13. Borrowings

	The Group		The Company	
	30-Sep-26 S$'000	31-Dec-25 S$'000	30-Sep-26 S$'000	31-Dec-25 S$'000
Short-term loans				
- Unsecured [(a)]	2,170	1,750	2,170	1,750
Long-term loans				
- Secured [(b)(c)]	155	308	-	-
	2,325	**2,058**	**2,170**	**1,750**
Represented by:				
Current	2,306	1,946	2,170	1,750
Non-current	19	112	-	-
	2,325	**2,058**	**2,170**	**1,750**

Total borrowings comprise the following:

(a) Short-term loans as at 30 September 2026, amounting to:

(i) S$900,000 (31 December 2025: S$900,000), with interest rate of 2.9% per annum (31 December 2025: 2.9%) over the bank's cost of funds, is unsecured;

(ii) S$850,000 (31 December 2025: S$750,000), with interest rate of 15% per annum, is unsecured and repayable within 12 months of 30 September 2026; and

(iii) S$420,000 (31 December 2025: S$100,000), with interest rate of 15% per annum, is unsecured and repayable within 12 months of 30 September 2026.

(b) Long-term loans as at 30 September 2026, amounting to:

(i) S$64,000 (31 December 2025: S$143,000) with interest rate of 4.0% (31 December 2025: 4.0%) per annum and repayable in 60 monthly instalments, is secured by a corporate guarantee from the Company;

(ii) S$48,000 (31 December 2025: S$95,000) with interest rate of 4.5% (31 December 2025: 4.5%) per annum and repayable in 60 monthly instalments, is secured by a personal guarantee from directors of a subsidiary of the Company; and

(iii) S$43,000 (31 December 2025: S$60,000) with interest rate of 7.8% (31 December 2025: 7.8%) per annum and repayable in 60 monthly instalments, is secured by a personal guarantee from directors of a subsidiary of the Company.

(c) As at 30 September 2026, a long term loan which amounted to S$6,000 as at 31 March 2026 (31 December 2025: S$10,000) with interest rate of 2.5% per annum and repayable in 60 monthly instalments, and was secured by a personal guarantee from a former director of a subsidiary of the Company, was fully repaid during 3Q2026.

14. Trade and other payables

	The Group		The Company	
	30-Sep-26	31-Dec-25	30-Sep-26	31-Dec-25
	S$'000	S$'000	S$'000	S$'000
Trade payables				
- third parties	133	110	-	-
Accrued expenses	657	388	592	325
Deferred consideration payable	40	40	-	-
Financial guarantee liabilities	-	-	153	153
Other payables	465	534	346	238
	1,162	962	1,091	716
	1,295	**1,072**	**1,091**	**716**

15. Revenue

	The Group		The Group	
	3Q2026	3Q2025	9M2026	9M2025
	S$'000	S$'000	S$'000	S$'000
Revenue from contracts with customers				
- Services rendered	369	346	1,089	1,020
Timing of revenue recognition				
- At a point in time	369	346	1,089	1,020

16. Other income

	The Group		The Group	
	3Q2026	3Q2025	9M2026	9M2025
	S$'000	S$'000	S$'000	S$'000
Government grants	-	-	5	13
Miscellaneous income	207	25	292	27
Interest income from bank	-*	-*	-*	-*
	207	25	297	40

* Amount is less than S$1,000.

17. Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. There was no income tax expense incurred for 3Q2026 and 9M2026, as well as 3Q2025 and 9M2025.

18. Loss for the period

Other than as disclosed elsewhere, loss for the period has been arrived at after charging/(crediting):

	The Group		The Group	
	3Q2026 S$'000	3Q2025 S$'000	9M2026 S$'000	9M2025 S$'000
Depreciation of property, plant and equipment	-*	-*	1	2
Amortisation of intangible assets	-*	-	2	-
Depreciation of right-of-use assets	16	15	46	46
Utilities expenses	3	-	21	2
Impairment of other receivables	-	2	14	-
Legal and professional fees	133	80	285	182
Short-term lease expenses	5	-	14	-

* Amount is less than S$1,000.

19. Financial assets and financial liabilities

The carrying amounts of financial assets and financial liabilities in each category are as follows:

	The Group		The Company	
	30-Sep-26 S$'000	31-Dec-25 S$'000	30-Sep-26 S$'000	31-Dec-25 S$'000
Financial assets				
Financial assets at amortised cost:				
- Trade and other receivables	1,188	1,226	40	40
- Cash and bank balances	162	194	32	51
	1,350	**1,420**	**72**	**91**
Financial liabilities				
Financial liabilities at amortised cost:				
- Loans and borrowings	2,325	2,058	2,170	1,750
- Lease liabilities	81	126	-	-
- Trade and other payables	1,295	1,072	1,091	716
	3,701	**3,256**	**3,261**	**2,466**

20. Financial instruments

Fair value

The face value less any estimated credit adjustments for financial assets and liabilities with a maturity of less than one year, comprising trade and other receivables (excluding input taxes), cash and bank balances, short-term borrowings, and trade and other payables (excluding provision for retirement benefits), are assumed to approximate their fair values. The fair value of financial liabilities is estimated by discounting the future contractual cash flows at the current market interest rate available to the Group and the Company for similar financial instruments.

Fair value hierarchy

The table below analyses financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3: inputs for the assets or liability that are not based on observable market data (unobservable inputs).

The fair values of the current financial assets and liabilities carried at amortised cost approximate their carrying amounts.

The carrying amount of the different categories of financial instruments is as disclosed on the face of statement of financial position, except for the following:

	Level 1 S$'000	Level 2 S$'000	Level 3 S$'000	Total S$'000
The Group				
At 30 September 2026				
Derivative financial asset	-	-	17	17
Other investments	-	-	-	-
Long-term loans	-	148	-	148
At 31 December 2025				
Derivative financial asset	-	-	17	17
Other investments	-	-	-	-
Long-term loans	-	284	-	284
The Company				
At 30 September 2026				
Derivative financial asset	-	-	17	17
Other investments	-	-	-	-
At 31 December 2025				
Derivative financial asset	-	-	17	17
Other investments	-	-	-	-

Derivative financial asset

The fair value of the put and call options is determined using a Black-Scholes option pricing model, adjusted for probability-weighted outcomes based on the contractual terms of the option agreement.

The valuation incorporates key inputs including share price, exercise price, expected volatility, risk-free interest rate and time to maturity. Expected volatility is derived from comparable listed healthcare companies, while the risk-free rate is based on Singapore government bond yields.

The valuation also incorporates management's assessment of the probability of conversion and vesting conditions being met.

As these inputs include significant unobservable assumptions, the instrument is classified within Level 3 of the fair value hierarchy.

Other investments

The Group holds unquoted equity investments which are designated at fair value through other comprehensive income as they are held for long-term strategic purposes.

The fair value of these investments is determined using a valuation approach based on the financial position and operating status of the investees. As at 31 December 2025, the investments were written down to $Nil based on management's assessment that the investees had ceased operations and were in net liabilities positions, with no expected recovery to equity holders.

As at 30 September 2026, the fair value of these investments remains at $Nil as there have been no significant changes in the financial condition or operating status of the investees.

These investments are classified within Level 3 of the fair value hierarchy as the valuation involves significant unobservable inputs.

Long-term loans

The fair values of long-term loans are determined using discounted cash flow analyses based on observable market interest rates for similar instruments with comparable credit risk and maturity. Accordingly, these instruments are classified within Level 2 of the fair value hierarchy.

21. Net asset value

	The Group		The Company	
	30-Sep-26	**31-Dec-25**	**30-Sep-26**	**31-Dec-25**
Net asset value per ordinary share (Singapore cents)	(0.15)	(0.10)	(0.23)	(0.17)
Number of shares at the end of the period/year ('000)	1,320,390	1,320,390	1,320,390	1,320,390
Net assets attributable to the owners of the Company (S$'000)	(1,927)	(1,349)	(3,094)	(2,279)

22. Subsequent events

On 26 October 2026, the Company entered into separate subscription agreements with Ms Wu Kai-Wen @ Cay Wu, Mr Chen Wei-Kai and Mr Teo Yi-Dar (collectively, the "**Subscribers**"), as announced by the Company on 26 October 2026. Pursuant to the subscription agreements, the Company agreed to allot and issue, and the Subscribers agreed to subscribe for, an aggregate of 640,000,000 new ordinary shares in the Company at an issue price of S$0.0036 per share, for an aggregate cash consideration of S$2,304,000. As at the date of this announcement, the Proposed Placement has not been completed and remains subject to the fulfilment of the conditions precedent under the respective subscription agreements. Please refer to the Company's announcement dated 26 October 2026 for further details on the Proposed Placement.

Save for the Proposed Placement disclosed above, there are no other known material events subsequent to 30 September 2026 and up to the date of this announcement that would require adjustment to or disclosure in these condensed interim consolidated financial statements.

F. OTHER INFORMATION REQUIRED PURSUANT TO APPENDIX 7C OF THE CATALIST RULES

1. Review

The condensed interim consolidated statement of financial position of Meta Health Limited (the "**Company**") and its subsidiaries (collectively, the "**Group**") as at 30 September 2026, and the related condensed interim consolidated statement of comprehensive income, statement of changes in equity and cash flow statement for the third quarter and nine-month financial period then ended, together with the accompanying explanatory notes, have not been audited or reviewed by the Company's auditors.

1A. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:

(a) Updates on the efforts taken to resolve each outstanding audit issue.
(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. The latest audited financial statements of the Company and the Group for the financial year ended 31 December 2025 were not subject to any adverse opinion, qualified opinion or disclaimer of opinion.

2. Review of performance of the Group

(A) Review of Statement of Comprehensive Income

Revenue

Revenue increased from (i) S$346,000 in 3Q2025 to S$369,000 in 3Q2026 and (ii) S$1.02 million in 9M2025 to S$1.09 million in 9M2026, mainly due to higher screening volumes delivered by Jas Medical.

Other income

Other income increased from (i) S$25,000 in 3Q2025 to S$207,000 in 3Q2026 and (ii) S$40,000 in 9M2025 to S$297,000 in 9M2026, mainly due to one-off income of approximately S$207,000 and S$292,000 recognised in 3Q2026 and 9M2026, respectively, arising from the recovery of losses related to irregularities concerning a subsidiary of the Group, Gainhealth Pte. Ltd. The one-off income comprised approximately S$7,000 and S$92,000 received as the final settlement payment during 3Q2026 and 9M2026, respectively, and approximately S$200,000 of non-cash income arising from the reversal of a pre-existing payable following the full receipt by the Group of all settlement sums.

Expenses

Cost of direct materials increased from S$69,000 in 9M2025 to S$84,000 in 9M2026, mainly due to higher screening volumes and an increase in average costs of materials used in health screenings. Cost of direct materials remained stable at S$28,000 in both 3Q2025 and 3Q2026.

Employee benefits expense decreased from (i) S$477,000 in 3Q2025 to S$281,000 in 3Q2026; and (ii) S$1.18 million in 9M2025 to S$865,000 in 9M2026, mainly due to the cost saving initiatives implemented at the corporate headquarter level, including reduction in headcount and changes in management's remuneration structure.

Finance costs increased from (i) S$35,000 in 3Q2025 to S$60,000 in 3Q2026 and (ii) S$83,000 in 9M2025 to S$163,000 in 9M2026, mainly due to higher average outstanding borrowings and increased interest expenses arising from the utilisation of borrowings bearing higher interest rates.

Other operating expenses increased from (i) S$231,000 in 3Q2025 to S$302,000 in 3Q2026 and (ii) S$689,000 in 9M2025 to S$788,000 in 9M2026, mainly due to legal and professional fees incurred in connection with the ongoing legal proceedings of the Group.

Loss after tax

The Group recorded a lower loss before taxation of S$111,000 in 3Q2026, compared to S$417,000 in 3Q2025, mainly due to the recognition of one-off recovery income and lower employee benefits expense, partially offset by higher finance costs and other operating expenses.

For 9M2026, the Group recorded a lower loss before taxation of S$563,000, compared to S$1.02 million in 9M2025, mainly due to higher other income arising from the one-off recovery and lower employee benefits expense, partially offset by higher finance costs and other operating expenses.

(B) Review of Statement of Financial Position

Right-of-use assets decreased from approximately S$122,000 as at 31 December 2025 to approximately S$76,000 as at 30 September 2026, mainly due to depreciation charges recognised in 9M2026.

Trade and other receivables decreased by approximately $38,000 from 31 December 2025 to 30 September 2026, mainly due to the impairment of legacy receivables associated with TS Medical, which was struck off during FY2025, as well as refunds of various deposits during 9M2026. Included in the trade and other receivables as at 30 September 2026 and 31 December 2025 were GST amounts of approximately S$1.1 million paid to the Royal Malaysian Customs Department, which the management of the Company has assessed to be recoverable. Please refer to Note 30 of the audited financial statements in the Group's Annual Report for FY2025 for further details.

Prepayments remained stable at S$13,000 as at 31 December 2025 and 30 September 2026.

Total borrowings (current and non-current) increased by approximately S$267,000 from 31 December 2025 to 30 September 2026, mainly due to additional drawdowns of borrowings from a controlling shareholder to support the Group's ongoing operations during 9M2026, partially offset by repayments of existing borrowings.

Lease liabilities (current and non-current) decreased by approximately S$45,000 from 31 December 2025 to 30 September 2026, mainly due to lease repayments made during 9M2026.

Trade and other payables increased from approximately S$1.07 million as at 31 December 2025 to approximately S$1.30 million as at 30 September 2026, mainly due to additional accruals for legal fees during 9M2026 relating to ongoing legal proceedings, partially offset by a decrease in other payables following the resolution of a pre-existing payable relating to the acquisition of remaining 15% shareholding of Gainhealth Pte. Ltd. in FY2022, as part of settlement arrangement in connection with Gainhealth Pte Ltd's irregularities. This waiver resulted in a reversal of payables of S$0.2 million into profit or loss.

As a result of the above, the Group recorded a negative working capital of approximately S$2.3 million as at 30 September 2026, as compared to a negative working capital of approximately S$1.6 million as at 31 December 2025. Please refer to Note 2 of Section E of this announcement for information on the Group's going concern assessment.

(C) Review of Cash Flows

3Q2026

Net cash used in operating activities in 3Q2026 of approximately S$28,000 was mainly attributable to an operating loss before working capital changes of approximately S$34,000, partially offset by a net working capital inflow of approximately S$6,000, mainly due to a decrease in trade and other receivables.

There was no net cash used in investing activities in 3Q2026, compared to net cash used in investing activities of approximately S$2,000 for 3Q2025.

Net cash used in financing activities in 3Q2026 of approximately S$53,000 was mainly due to interest payments of approximately S$60,000, repayment of borrowings of approximately S$48,000 and repayment of lease liabilities of approximately S$15,000, partially offset by proceeds from borrowings of approximately S$70,000.

As a result of the above and after accounting for exchange translation differences, the Group's cash and cash equivalents decreased from approximately S$247,000 as at 1 July 2026 to approximately S$162,000 as at 30 September 2026.

9M2026

Net cash used in operating activities in 9M2026 of approximately S$90,000 was mainly attributable to an operating loss before working capital changes of approximately S$337,000, partially offset by a net working capital inflow of approximately S$247,000, mainly due to an increase in trade and other payables.

There was no net cash used in investing activities in 9M2026.

Net cash provided by financing activities in 9M2026 of approximately S$59,000 was mainly due to proceeds from borrowings of approximately S$420,000, partially offset by interest payments of approximately S$163,000, repayment of borrowings of approximately S$153,000 and repayment of lease liabilities of approximately S$45,000.

As a result of the above and after accounting for exchange translation differences, the Group's cash and cash equivalents decreased from approximately S$194,000 as at 1 January 2026 to approximately S$162,000 as at 30 September 2026.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable as the Company did not disclose any forecast or prospect statement to shareholders previously.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the Group operates and any known factors or events that may affect the Group in the next reporting period and the next 12 months

The Company remains focused on identifying new business opportunities to expand the revenue streams of the Group. The Company continues to actively evaluate and engage in discussions on potential acquisition opportunities. To support the Group's growth plans, the Company may also consider carrying out potential fundraising exercises. In this regard, the Company had, on 26 October 2026, announced the Proposed Placement to raise gross proceeds of approximately S$2.30 million, which remains subject to completion as at the date of this announcement. Please refer to Note 22 of Section E of this announcement and the Company's announcement dated 26 October 2026 for further details on the Proposed Placement.

With respect to the Group's operating business, the Company anticipates potential headwinds arising from stiffening competition in the local market, and customers' cautious spending amid an inflationary environment. Meanwhile, the management continues to focus on cost control initiatives, including reviewing operational processes and renegotiating vendor arrangements to improve operational leverage.

5. Dividend information

(a) Any dividend recommended/declared for the current financial period reported on?

Nil.

(b) Any dividend recommended/declared for the corresponding period of the immediately preceding financial year?

Nil.

(c) Date payable

Not applicable.

(d) Record date

Not applicable.

6. If no dividend has been declared/recommended, a statement to the effect and the reason(s) for the decision.

No dividend has been declared or recommended for 3Q2026 and 9M2026, as the Group recorded a loss for 3Q2026 and 9M2026.

7. Interested person transactions ("IPTs")

The Group did not obtain a general mandate from its shareholders for IPTs. There was no IPT entered into by the Group with a value of S$100,000 or more during 3Q2026 and 9M2026.

8. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Catalist Rule 720(1)

The Company confirms that all the required undertakings under Rule 720(1) of the Catalist Rules have been obtained from all its directors and executive officers in the format set out in Appendix 7H of the Catalist Rules.

9. Disclosure pursuant to Catalist Rule 706A

The Company did not acquire or dispose of any shares in an entity which would result in that entity becoming or ceasing to be a subsidiary or associated company of the Group, or result in a change in the Group's shareholding percentage in a subsidiary or associated company during 3Q2026 and 9M2026.

10. Confirmation by the Board pursuant to Catalist Rule 705(5)

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim consolidated financial statements of the Group for the third quarter and nine-month financial period ended 30 September 2026 to be false or misleading in any material aspect.

On behalf of the Board of Directors

Ng Yeau Chong Independent Non-Executive Chairman	Law Ren Kai Kenneth Non-Independent Non-Executive Director

12 November 2026